Medesis Pharma S.A.

Regulatory Filings • Jul 4, 2023

MEDESIS PHARMA: NOTICE OF ALLOWANCE IN THE UNITED STATES OF THE PATENT PROTECTING THE RADIATION PROTECTION TREATMENT AGAINST IRRADIATION DURING A NUCLEAR ACCIDENT

Montpellier, France, July 4th, 2023 at 8:00am CET - MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary delivery technology of active ingredients in nano micelles by buccal route, Aonys®, announces that it has received the agreement ("Notice of Allowance") for the registration in the United States of its patent protecting for 20 years the property of its drug candidate for radiation protection NanoManganese.

MEDESIS PHARMA is developing a radiomitigation treatment administered during or within minutes/hours following overexposure to ionizing radiation. It is intended for the treatment of civilian and military personnel (dual technology) subjected to irradiation, whether of industrial, accidental, or military origin, and whether external or internal (name NP02-NanoManganese®).

The preclinical studies were carried out in collaboration with the Biomedical Research Institute of the Armed Forces (IRBA) in France.

Studies have been carried out on irradiated animals, with very favorable results allowing survival of all animals during irradiation at an LD50 dose (50% of animals die within 10 days). A very important element in radiation protection, the activity is observed in radiomitigation, i.e. effective when administration takes place within 24 hours of irradiation.

This product is suitable for emergency situations:

• · Radiation mitigating effect (effective after irradiation)
• · Ease of administration (buccal route)
• · Suitable for children, including children under 2 years old
• No toxicity expected
• · Easy to store in bulk (stable at room temperature)
• Ease of deployment (100 ml bottles)
• Low industrial cost price

MEDESIS PHARMA has entrusted FREEMIND Group with seeking funding from the US government in order to finalize the development of this product.

This patent is also pending in Europe, Canada, Japan, China, Eurasian Federation, Israel, India, Australia, Brazil, and South Africa.

About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and resistant cancers.

Medesis Pharma is also developing treatments decicated to populations contaminated or irracliated after a civil CALYPTUS or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific Tel : +33 1 53 65 68 66 publications, holds 12 patent families and 72 patents, resulting from 20 years of research.

Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP

For more information: www.medesispharma.com

MFDFSIS PHARMA Jean Claude Maurel Tel: +33 4 67 03 03 96 contact@medesispharma.com

Marie Calleux medesispharma@calvotus.net